Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors. - Test2 - elhamkhani - TriplyDB

Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.

Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.

http://www.wikidata.org/entity/Q37140621

about

Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival.Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Safety and efficacy evaluation of pertuzumab in patients with solid tumors Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan.Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer.Pertuzumab: new hope for patients with HER2-positive breast cancer.Monoclonal antibodies in lung cancer.Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.Pertuzumab for the treatment of metastatic breast cancer.Pertuzumab for the treatment of breast cancer.Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.Pertuzumab in gastrointestinal cancer.Pertuzumab for the treatment of breast cancer: a safety review.

P2860

Q28083123-20A4B1C6-0EF6-4DF1-AD87-869F8B208E5F Q28237833-3ADEC92A-3A2D-4CC5-AA6A-0D4D6651B058 Q30376023-5BF8CDF4-4C2C-4FAA-A927-25CC92733AC4 Q33618685-8BA04843-5146-4859-A51A-AE4B33C95D95 Q33680109-11FA1D30-26FD-4B0A-A5E0-76EF590D5CAD Q33714388-D1B95B92-AA61-4BCC-82DC-9686A9729749 Q36336483-7459850D-CAC3-48E8-86FE-59C6E8F6C17F Q37205749-80615B72-25A8-4012-9CFE-E48EBC1FBE3E Q37639279-7C759CEA-D0E0-405D-91FA-FE6352F26FE3 Q37970020-15AF2E72-FDA3-4FAE-99A9-3E3470229365 Q37982433-C2C7B727-FAED-489E-9606-7D2F95B2C9D3 Q38036549-18E53523-C234-41A7-BDAF-094AABD841BB Q38067454-6070F7E5-766B-4680-8F92-F33F0277BA4B Q38119307-544B0754-0C0A-4EFA-8669-91AD28E9CE4A Q38123762-1D2EA7EB-C9B1-48FF-9472-4BD9BD579D78 Q38126859-A1FFA47B-C3FE-4407-9196-851741D4C7CF Q38132047-FDF4E1E2-E013-401C-8626-C1017148F4AF Q38132237-C26DA8DE-96FA-44B3-95A1-76C9CD4F299D Q38219674-62E031F9-1B0D-40E0-B7E9-85B058E3F43E Q38286163-97E66BF1-10B2-4A9A-A397-AA4E6BB44FF5 Q38364462-5F3715DF-E7D1-4A8B-B321-83A016BC7235 Q38373931-F6503809-C4E6-43BB-A483-19873CF5D1F7 Q38573858-101BFE5B-45BF-4AB8-B85C-C83E2F1A1FB8 Q38653309-FE471D40-B57E-4BF4-9D23-9F3E441A59BA Q38776876-A2FAEE79-9A30-47CB-8CA0-9A6E095D4380

P2860

Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.

http://www.wikidata.org/entity/Q37140621

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase I and pharmacokinetic st ...... se patients with solid tumors.

@en

Phase I and pharmacokinetic st ...... se patients with solid tumors.

@nl

type

label

Phase I and pharmacokinetic st ...... se patients with solid tumors.

@en

Phase I and pharmacokinetic st ...... se patients with solid tumors.

@nl

prefLabel

Phase I and pharmacokinetic st ...... se patients with solid tumors.

@en

Phase I and pharmacokinetic st ...... se patients with solid tumors.

@nl

P1433

Q37140621-4C06E332-8038-4AEE-883A-4A264C9B500B

P1476

Q37140621-0B44C549-E502-4968-926E-B35BAD808004

P2093

Q37140621-0527133E-761B-4D39-BCD1-1FF76BCE152B

Q37140621-0B36C37A-B0D7-4442-AF92-0AEB992F0AE9

Q37140621-92EAE01F-2694-46B9-97FD-BCA0CCEA8013

Q37140621-C12CD939-70C8-4A20-9B98-51ECDF21109C

Q37140621-C8E25AA5-4078-4C4E-B622-FADECA707C5A

Q37140621-DAC2FACD-A138-4024-877B-2FEA5D47B61B

Q37140621-FCF02DD9-77DA-47D5-80C6-9A6D1504CECF

P2860

Q37140621-1048433F-F9EF-49BE-8E87-5AEF9436628C

Q37140621-1AED9CEC-4DF0-453C-8969-218CEA071D93

Q37140621-2D633D6D-77A2-4695-9F23-3C422E9DF3F9

Q37140621-2E1C8AED-CF19-4CAC-B91F-ADC4643DB94C

Q37140621-3487E874-CE42-4A5F-90D4-3D8B95D4197A

Q37140621-34B76552-76F3-4DA2-9E53-8A266E4932F6

Q37140621-34C7978F-CF4C-467B-BEFE-A3656C30E430

Q37140621-586B0F1F-82A8-4C9E-A530-79FA414E6831

Q37140621-65BDF8DF-C0B7-47A6-A802-140BF59D532C

Q37140621-6FD1FC45-34C7-449D-A75F-D306BD3BBAF6

P304

Q37140621-D291823F-E0C1-4997-903D-1BA035C63A82

P31

Q37140621-CDFF2128-A563-447B-B6CB-DA7CD574C309

P356

Q37140621-DAB012A3-5045-45D4-B319-68B2197625CC

P433

Q37140621-9C64936E-DC6D-409E-B9E7-222B41EEAA32

P478

Q37140621-758D6D16-A251-43CE-A5AE-567F0A416B45

P577

Q37140621-11474CE4-1657-4926-A110-E9436EA3D006

P5875

Q37140621-75B1CCBC-EF9D-4F42-A5BB-A3634DDB6FB2

P698

Q37140621-F03532E6-7A1E-4A0C-9C25-3B64B8486AF5

P921

Q37140621-d0679696-4316-15cf-82ed-e558d4501ea0

P932

Q37140621-B5AE244D-93D7-4839-AAD1-3767DAFB8865

P356

P1433

Japanese Journal of Clinical Oncology

P1476

Phase I and pharmacokinetic st ...... se patients with solid tumors.

@en

P2093

Kazuhiko Yamada

http://www.w3.org/2001/XMLSchema#string

Noboru Yamamoto

http://www.w3.org/2001/XMLSchema#string

Tomohide Tamura

http://www.w3.org/2001/XMLSchema#string

Toshio Shimizu

http://www.w3.org/2001/XMLSchema#string

Yasuhide Yamada

http://www.w3.org/2001/XMLSchema#string

Yasuhito Fujisaka

http://www.w3.org/2001/XMLSchema#string

Yutaka Fujiwara

http://www.w3.org/2001/XMLSchema#string

P2860

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Untangling the ErbB signalling network

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

A potential role for activated HER-2 in prostate cancer.

The EGF receptor family as targets for cancer therapy.

P304

260-266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JJCO/HYP006

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2009-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24177711

http://www.w3.org/2001/XMLSchema#string

P698

19261664

http://www.w3.org/2001/XMLSchema#string

P921

P932

2661001

http://www.w3.org/2001/XMLSchema#string